Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BGM NASDAQ:CRDF NASDAQ:ELVN NASDAQ:GPCR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBGMBGM Group$8.60+1.7%$11.66$5.26▼$17.17$822.50M1.2782,588 shs56,254 shsCRDFCardiff Oncology$2.64+11.4%$3.59$2.01▼$5.64$157.67M1.552.75 million shs5.87 million shsELVNEnliven Therapeutics$18.73-0.4%$20.68$13.30▼$30.03$922.99M0.93376,154 shs490,125 shsGPCRStructure Therapeutics$17.59-1.2%$20.43$13.22▼$45.37$1.02B-1.87728,968 shs571,199 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBGMBGM Group+1.65%-17.70%-11.89%-26.50%+859,999,900.00%CRDFCardiff Oncology+11.39%-33.50%-26.46%-6.38%+12.82%ELVNEnliven Therapeutics-0.43%-11.65%-9.25%-8.68%-29.00%GPCRStructure Therapeutics-1.18%-1.95%-13.94%-35.07%-52.96%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBGMBGM GroupN/AN/AN/AN/AN/AN/AN/AN/ACRDFCardiff Oncology1.797 of 5 stars3.40.00.00.02.51.70.6ELVNEnliven Therapeutics2.469 of 5 stars3.52.00.00.01.44.20.0GPCRStructure Therapeutics2.0602 of 5 stars3.51.00.00.02.21.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBGMBGM Group 0.00N/AN/AN/ACRDFCardiff Oncology 2.83Moderate Buy$11.70343.18% UpsideELVNEnliven Therapeutics 3.00Buy$41.20119.97% UpsideGPCRStructure Therapeutics 3.00Buy$76.17333.01% UpsideCurrent Analyst Ratings BreakdownLatest CRDF, ELVN, GPCR, and BGM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/8/2025CRDFCardiff OncologyLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$19.007/2/2025ELVNEnliven TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$40.00 ➝ $48.006/24/2025CRDFCardiff OncologyJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageHold$3.506/23/2025GPCRStructure TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$65.006/23/2025GPCRStructure TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$89.006/18/2025CRDFCardiff OncologyWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform6/16/2025ELVNEnliven TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$40.00 ➝ $52.006/16/2025ELVNEnliven TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$37.005/16/2025ELVNEnliven TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$36.00 ➝ $27.005/15/2025ELVNEnliven TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$39.00 ➝ $40.005/12/2025GPCRStructure TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$80.00 ➝ $75.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBGMBGM Group$25.10M33.31N/AN/A$7.34 per share1.17CRDFCardiff Oncology$680K258.29N/AN/A$0.88 per share3.00ELVNEnliven TherapeuticsN/AN/AN/AN/A$6.34 per shareN/AGPCRStructure TherapeuticsN/AN/AN/AN/A$15.10 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBGMBGM Group-$1.44MN/A0.00∞N/AN/AN/AN/AN/ACRDFCardiff Oncology-$45.43M-$0.87N/AN/AN/A-9,344.14%-77.94%-63.65%8/14/2025 (Estimated)ELVNEnliven Therapeutics-$89.02M-$1.92N/AN/AN/AN/A-31.84%-30.09%8/12/2025 (Estimated)GPCRStructure Therapeutics-$122.53M-$0.87N/AN/AN/AN/A-16.35%-15.71%8/6/2025 (Estimated)Latest CRDF, ELVN, GPCR, and BGM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025CRDFCardiff Oncology-$0.19N/AN/AN/A$0.10 millionN/A8/14/2025Q2 2025GPCRStructure Therapeutics-$0.28N/AN/AN/AN/AN/A8/12/2025Q2 2025ELVNEnliven Therapeutics-$0.54N/AN/AN/AN/AN/A7/29/2025Q2 2025CRDFCardiff Oncology-$0.19-$0.21-$0.02-$0.21$0.11 million$0.12 million5/14/2025Q1 2025ELVNEnliven Therapeutics-$0.51-$0.57-$0.06-$0.57N/AN/A5/8/2025Q1 2025CRDFCardiff Oncology-$0.19-$0.20-$0.01-$0.20$0.09 million$0.11 million5/8/2025Q1 2025GPCRStructure Therapeutics-$0.24-$0.27-$0.03-$0.27N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBGMBGM GroupN/AN/AN/AN/AN/ACRDFCardiff OncologyN/AN/AN/AN/AN/AELVNEnliven TherapeuticsN/AN/AN/AN/AN/AGPCRStructure TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBGMBGM GroupN/A1.821.45CRDFCardiff OncologyN/A4.426.22ELVNEnliven TherapeuticsN/A21.0721.06GPCRStructure TherapeuticsN/A23.2923.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBGMBGM GroupN/ACRDFCardiff Oncology16.29%ELVNEnliven Therapeutics95.08%GPCRStructure Therapeutics91.78%Insider OwnershipCompanyInsider OwnershipBGMBGM Group58.66%CRDFCardiff Oncology7.70%ELVNEnliven Therapeutics25.90%GPCRStructure Therapeutics9.43%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBGMBGM Group29897.22 million40.19 millionN/ACRDFCardiff Oncology2066.53 million61.40 millionOptionableELVNEnliven Therapeutics5049.07 million36.36 millionOptionableGPCRStructure Therapeutics13657.34 million51.94 millionOptionableCRDF, ELVN, GPCR, and BGM HeadlinesRecent News About These CompaniesFederated Hermes Inc. Sells 875,010 Shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR)August 2 at 5:13 AM | marketbeat.comUniversal Beteiligungs und Servicegesellschaft mbH Lowers Stock Holdings in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR)August 2 at 4:50 AM | marketbeat.comStructure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Receives $76.17 Consensus Target Price from BrokeragesJuly 31 at 2:37 AM | americanbankingnews.comStructure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Recommendation of "Buy" by BrokeragesJuly 28, 2025 | marketbeat.comReadystate Asset Management LP Increases Stock Position in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR)July 22, 2025 | marketbeat.comPrincipal Financial Group Inc. Lowers Holdings in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR)July 13, 2025 | marketbeat.comStructure Therapeutics (NASDAQ:GPCR) Trading Down 7.3% - Here's WhyJuly 7, 2025 | marketbeat.comStructure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Receives Average Rating of "Buy" from BrokeragesJuly 3, 2025 | marketbeat.comJefferies Reiterates a Buy Rating on Structure Therapeutics (GPCR) With a $79 PTJune 24, 2025 | msn.comStructure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671June 20, 2025 | globenewswire.comStructure Therapeutics: Why Aleniglipron's Path To Market Remains TreacherousJune 10, 2025 | seekingalpha.comStructure Therapeutics Reports First Quarter 2025 Financial Results and Recent HighlightsMay 9, 2025 | finance.yahoo.comCitigroup Initiates Coverage of Structure Therapeutics Inc. - Depositary Receipt () (GPCR) with Buy RecommendationMay 3, 2025 | msn.comStructure draws new Buy at Citi on oral obesity drug pipelineMay 2, 2025 | msn.comViking among notable gainers as Pfizer raises deal prospectsApril 29, 2025 | msn.comIs Structure Therapeutics Inc. (NASDAQ:GPCR) the Most Promising Small-Cap Stock According to Analysts?April 26, 2025 | msn.comH.C. Wainwright maintains buy on Structure Therapeutics sharesApril 24, 2025 | uk.investing.comResearchers crack the code of cell movementApril 24, 2025 | sciencedaily.comSEli Lilly jumps as results from weight-loss pill study rival competitor’sApril 17, 2025 | markets.businessinsider.comWhy did Lilly data for oral GLP-1 boost Structure and Metsera?April 17, 2025 | seekingalpha.comSA Asks: What's the best weight-loss drug stock right now?April 17, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCRDF, ELVN, GPCR, and BGM Company DescriptionsBGM Group NASDAQ:BGM$8.60 +0.14 (+1.65%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$8.26 -0.34 (-4.01%) As of 08/1/2025 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. Qilian International Holding Group Limited was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.Cardiff Oncology NASDAQ:CRDF$2.64 +0.27 (+11.39%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.66 +0.02 (+0.61%) As of 08/1/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.Enliven Therapeutics NASDAQ:ELVN$18.73 -0.08 (-0.43%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$18.72 -0.02 (-0.08%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.Structure Therapeutics NASDAQ:GPCR$17.59 -0.21 (-1.18%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$17.60 +0.02 (+0.09%) As of 08/1/2025 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
